The adoption of decentralized and agile clinical trials has increased exponentially over the past few years. As adoption accelerates, so do the possibilities that a decentralized clinical trial (DCT) enables. Oncology trials have especially benefited from DCT practices.
Dr. Shaalan Beg, MD, MS, Vice President, Oncology, at Science 37 met recently with Dr. Aasma Shaukat, Professor of Gastroenterology and Medicine, NYU Grossman School of Medicine, and Andrew J. Mckenzie, Ph.D., Vice President, Personalized Medicine, Sarah Cannon for a discussion on what current clinical research looks like with oncology trials.
The panel spoke about the shared value that agile approaches to clinical trials deliver to patients, sponsors, sites, and CROs — giving examples of how decentralized elements are incorporated in oncology trials today, and how the landscape will change in the years to come.
Register to access this video-on-demand to learn what oncology trials look like now with the adoption of decentralized practices